Steroids in acute exacerbations of chronic obstructive pulmonary disease: are nebulized and systemic forms comparable?

Basit Öğe Kaydı
dc.authoridAkgün, Metin/0000-0003-3404-4274
dc.authoridGunen, Hakan/0000-0001-6631-4457
dc.authoridMeral, Mehmet/0000-0003-4476-9922
dc.authorwosidAkgün, Metin/A-9993-2008
dc.authorwosidGunen, Hakan/HKV-9202-2023
dc.contributor.authorGunen, Hakan
dc.contributor.authorMirici, Arzu
dc.contributor.authorMeral, Mehmet
dc.contributor.authorAkgun, Metin
dc.date.accessioned2024-08-04T20:31:09Z
dc.date.available2024-08-04T20:31:09Z
dc.date.issued2009
dc.departmentİnönü Üniversitesien_US
dc.description.abstractPurpose of review Systemic corticosteroids are strongly recommended in the treatment of exacerbations of chronic obstructive pulmonary disease (COPD). As COPD patients are usually elderly and are relatively immobile, side effects of systemic corticosteroids frequently outweigh their beneficial effects. On the contrary, nebulized corticosteroid solutions have a negligible systemic side-effect profile. In this review, as an alternative to systemic corticosteroids, the place of nebulized corticosteroids in exacerbation periods of COPD was summarized. Recent findings The number of trials in the literature is increasing. Regarding the available data, high dose nebulized budesonide was found as effective as systemic corticosteroids in exacerbations of COPD. The side-effect profile, blood glucose level in particular, is better for nebulized budesonide. Summary Findings from recent studies are giving a positive impression on the role of high dose nebulized budesonide in exacerbations of COPD. However, larger and statistically high powered trials testing different types of nebulized corticosteroid solutions with varying dosages are still lacking. Before recommending the routine use of nebulized corticosteroids in exacerbations, present findings need to be confirmed with further studies of high quality.en_US
dc.identifier.doi10.1097/MCP.0b013e32832185da
dc.identifier.endpage137en_US
dc.identifier.issn1070-5287
dc.identifier.issue2en_US
dc.identifier.pmid19532028en_US
dc.identifier.scopus2-s2.0-62349085566en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage133en_US
dc.identifier.urihttps://doi.org/10.1097/MCP.0b013e32832185da
dc.identifier.urihttps://hdl.handle.net/11616/94764
dc.identifier.volume15en_US
dc.identifier.wosWOS:000264280700009en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofCurrent Opinion in Pulmonary Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectefficacy of nebulized corticosteroidsen_US
dc.subjectexacerbations of chronic obstructive pulmonary diseaseen_US
dc.subjectnebulized budesonideen_US
dc.subjectnebulized corticosteroidsen_US
dc.subjectside effects of nebulized corticosteroidsen_US
dc.titleSteroids in acute exacerbations of chronic obstructive pulmonary disease: are nebulized and systemic forms comparable?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu